Treprostinil Palmitil ( DrugBank: Treprostinil )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
86肺動脈性肺高血圧症4

86. 肺動脈性肺高血圧症


臨床試験数 : 1,205 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05649748
(ClinicalTrials.gov)
February 28, 20236/12/2022A Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial HypertensionPulmonary Arterial HypertensionDrug: Treprostinil Palmitil;Drug: PlaceboInsmed IncorporatedNULLRecruiting18 YearsN/AAll100Phase 2/Phase 3Japan
2NCT05147805
(ClinicalTrials.gov)
August 24, 202224/11/2021A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial HypertensionA Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial HypertensionPulmonary Arterial HypertensionDrug: Treprostinil Palmitil;Drug: PlaceboInsmed IncorporatedNULLRecruiting18 Years75 YearsAll99Phase 2United States;Argentina;Australia;Austria;Belgium;Brazil;Denmark;Germany;Italy;Japan;Malaysia;Mexico;Philippines;Serbia;Spain;Switzerland;United Kingdom
3JPRN-jRCT2071220033
02/08/202202/08/2022A Randomized, Double-Blind, Placebo-Controlled Study of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial HypertensionA Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension Pulmonary Arterial HypertensionExperimental: Treprostinil Palmitil Inhalational Powder
Participants will be administered TPIP once per day at a starting dose of 80 micrograms. Participants will be titrated to the highest tolerated dose for each individual participant of between 80 micrograms and 640 micrograms during the initial 3 weeks of treatment. The overall treatment period will be 16 weeks.

Placebo Comparator: Placebo
Participants will be administered a placebo matching TPIP once per day for 16 weeks.
F IsmatNULLRecruiting> 18age old< 75age oldBoth99Phase 2United States;Argentina;Australia;Mexico;Phillipines;Japan
4NCT04791514
(ClinicalTrials.gov)
March 29, 20228/3/2021A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)An Open-Label Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial HypertensionPulmonary Arterial HypertensionDrug: Treprostinil PalmitilInsmed IncorporatedNULLTerminated18 YearsN/AAll1Phase 2United States